Delving into the Latest Updates on Furazolidone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3-(5'-Nitrofurfuralamino)-2-oxazolidone, 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone, 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone

+ [10]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOther Diseases

Active Indication

CholeraDysenteryEnteritis+ [3]

Inactive Indication-

Originator Organization

Shire Development LLC

Active Organization

Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.

Inactive Organization

Shire Development LLC

Drug Highest PhaseApproved

First Approval Date

US (20 Jan 1958),

Enteritis

Regulation-

Login to view timeline

Structure

Molecular FormulaC8H7N3O5

InChIKeyPLHJDBGFXBMTGZ-UHFFFAOYSA-N

CAS Registry67-45-8

The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:
* Main indicators: the eradication rate of Helicobacter pylori for eradication.
* Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.

Start Date04 Sep 2023

Sponsor / Collaborator-

IRCT20230202057305N1 / SuspendedPhase 2IIT

Comparison of efficacy and safety of quadruple regimens containing furazolidone in patients with Helicobacter pylori infection

Start Date03 Apr 2023

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with Furazolidone

Login to view more data

100 Translational Medicine associated with Furazolidone

Login to view more data

100 Patents (Medical) associated with Furazolidone

Login to view more data

1,690

Literatures (Medical) associated with Furazolidone

01 Nov 2024·International Journal of Antimicrobial Agents

Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis

Review

Author: Zeng, Shuyan ; Yang, Xiaoyun ; Li, Yueyue ; Nan, Xueping ; Zuo, Xiuli ; Li, Yanqing ; Wu, Xiaoqi ; Duan, Miao ; Kong, Qingzhou

BACKGROUNDEmpirical treatment needs to be supported by regional data, but knowledge of interregional differences is currently lacking in China. This study aimed to summarize and map the primary and secondary antibiotic resistance of Helicobacter pylori in different regions of mainland China.METHODSPubMed, EMBASE, Web of Science, China National Knowledge Infrastructure and Wanfang databases were systematically reviewed for studies published between 1 January 2000 and 15 July 2023. Data related to primary and secondary H. pylori antibiotic resistance rates were included. Random-effects models were used to synthesize the pooled resistance rates.RESULTSUltimately, 74 studies were included in the final analysis. A total of 16 provinces reported resistance data. The overall resistance rates of H. pylori in mainland China were 30.72% (95% CI 27.53%-33.99%) to clarithromycin, 70.14% (95% CI 29.53%-37.46%) to metronidazole and 32.98% (95% CI 28.73%-37.37%) to levofloxacin; for amoxicillin, tetracycline, and furazolidone, the rates were 2.41% (95% CI 1.43%-3.60%), 2.53% (95% CI 1.19%-4.28%) and 1.54% (95% CI 0.28%-3.62%), respectively. Spatial and temporal differences were observed. The resistance rates increased after treatment failure; however, secondary resistance to amoxicillin, tetracycline and furazolidone were still low across the vast majority of study regions.CONCLUSIONSurveillance of the updated prevalence of antibiotic resistance of H. pylori for different regions is warranted, which should factor into clinical decision making and guideline recommendations.

01 Nov 2024·Food Chemistry

Synthesis of P, N-dopped carbon nanosheets for highly sensitive fluorescence analysis of nitrofuran antibiotics in fish

Article

Author: Li, Zhuo ; Dai, Jing ; Guo, Xinrong ; Yang, Huan ; Huang, Huiqun ; Yao, Wen ; Huang, Hongyuan ; Yang, Jie

The misuse of antibiotics has caused serious impacts on food safety and human health, making it crucial to develop rapidly and highly sensitive methods for detecting trace nitrofuran antibiotics (NFs). In this study, phosphorus, nitride-doped carbon nanosheets (PN/CNs) were synthesized using a simple hydrothermal method based on graphitic carbon nitride. This prepared material showed excellent water solubility and stable optical properties. A new fluorescence sensing platform based on PN/CNs was constructed for the highly sensitive detection of four NFs. This sensitivity was mainly attributed to the fluorescence resonance energy transfer (FRET) mechanism. The limits of detection for nitrofurazone, nitrofurantoin, furazolidone and furaltadone were determined to be 13.41, 15.24, 16.37 and 19.94 nM, respectively. The high sensitivity and selectivity of PN/CNs for these four NFs were thoroughly evaluated by the Stern-Volmer equation and FRET quenching efficiency. This proposed method exhibited high sensitivity and can be successfully applied to detect NFs in fish.

22 Oct 2024·mSystems

Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)

Article

Author: Lu, Mengxiong ; Mei, Chunfeng ; Chen, Ting ; Wang, Fengyun ; Xue, Hong ; Han, Lili ; Li, Xuan ; Wang, Yitian ; Tang, Xudong

ABSTRACT Lactose intolerance (LI) is a prevalent condition characterized by gastrointestinal symptoms that arise following lactose consumption. Recent evidence suggests that the gut microbiome may influence lactose levels in the gut. However, there is limited understanding regarding the alterations in microbiota and metabolism between individuals with LI and non-LI. This study conducted a paired-sample investigation utilizing data from the American Gut Project (AGP) and performed metagenomic and untargeted metabolomic analyses in a Chinese cohort to explore the interaction between the gut microbiome and serum metabolites. In addition, fecal microbiota transplantation (FMT) experiments were conducted to further examine the impact of the LI-associated gut microbiome on inflammatory outcomes. We identified 14 microbial genera that significantly differed between LI and controls from AGP data. Using a machine learning approach, group separation was predicted based on seven species and nine metabolites in the Chinese cohort. Notably, increased levels of Escherichia coli in the LI group were negatively correlated with several metabolites, including PC (22:6/0:0), indole, and Lyso PC, while reduced levels of Faecalibacterium prausnitzii and Eubacterium rectale were positively correlated with indole and furazolidone. FMT-LI rats displayed visceral hypersensitivity and an altered gut microbiota composition compared to FMT-HC rats. Metagenomic and metabolomic analyses revealed an enrichment of MAPK signaling in LI, which was confirmed by FMT-LI rats showing higher expression of ERK and RAS, along with increased concentrations of proinflammatory cytokines. This study provides valuable insights into the disrupted microbial and metabolic traits associated with LI, emphasizing potential microbiome-based approaches for its prevention and treatment. IMPORTANCELactose intolerance (LI) is a prevalent condition characterized by gastrointestinal symptoms after lactose consumption due to a deficiency of lactase. There is limited understanding regarding the microbiota and metabolic alterations between individuals with LI and non-LI. This study represents the first exploration to investigate metagenomic and metabolomic signatures among subjects with lactose intolerance as far as our knowledge. We identified 14 microbial genera in the Western cohort and 7 microbial species, along with 9 circulating metabolites in the Chinese cohort, which significantly differed in LI patients. Metagenomic and metabolomic analyses revealed an enrichment of MAPK signaling in LI patients. This finding was confirmed by FMT-LI rats, exhibiting increased expression of ERK and RAS, along with higher concentrations of pro-inflammatory cytokines. Our study provides insights into the disrupted functional and metabolic traits of the gut microbiome in LI, highlighting potential microbiome-based approaches for preventing and treating LI.

100 Deals associated with Furazolidone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00830	Furazolidone	G01AX06	DB00614

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cholera	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Dysentery	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Enteritis	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Giardiasis	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Trichomonas Infections	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981
Typhoid Fever	CN	Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd.	01 Jan 1981

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| J Gastroenterol Hepatol	Not Applicable	-	-	Clarithromycin-based bismuth-containing quadruple therapy (C-BQT)	ldxzoyedrd(lqyzhgncdo) = Frequencies of adverse events in F-BQT and C-BQT had no differences (36.0% in C-BQT vs 32.6% in F-BQT, P = 0.499) azyifutvre (qcptvhohiq )	Positive	01 Sep 2021
				Furazolidone-based bismuth-containing quadruple therapy (F-BQT)
NCT03609892 (Pubmed \| J Dig Dis)	Phase 4	-	658	Amoxicillin plus berberineAmoxicillin plus berberine	mwihrnqqqe(mtoefcjmdd) = qjyhgjlera nocbkrsjep (cucizmfhjl ) View more	Negative	01 May 2020
				Tetracycline plus furazolidone	mwihrnqqqe(mtoefcjmdd) = nzlguqgmms nocbkrsjep (cucizmfhjl ) View more
NCT00520949 (Pubmed \| Dig Dis Sci)	Not Applicable	Helicobacter pylori infection Second line	176	Triple therapy	sdnbiytqvw(qgriiuwahl) = aoeyfbxejo hnienrqupn (hxohqobuld )	-	01 Sep 2009
				Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole	sdnbiytqvw(qgriiuwahl) = ulaglzsksm hnienrqupn (hxohqobuld )